Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
Ultragenyx agreed to sell a Rare Pediatric Disease Priority Review Voucher for $203 million in non-dilutive funding. The PRV was earned from the FDA approval of FAYUVI (UX111), the first FDA-approved treatment for MPS IIIA (Sanfilippo syndrome Type A).
Key figures
- Drug Name
- FAYUVI (rebisufligene etisparvovec-hopf) / UX111
- Deal Value Usd
- 203000000
- Prv type
- Rare Pediatric Disease Priority Review Voucher
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.